Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Illumina Inc. has had a strong first quarter of 2024, which included an encouraging performance from its high throughput consumables, increased revenue from strategic partnerships, and the delivery of a number of NovaSeq X instruments.</li><li>However, Chief Executive Officer Jacob Thaysen has warned about the persisting uncertain global economic environment and cited customer concerns affecting purchasing decisions.</li><li>The year's results were particularly promising considering the challenges posed by the Coronavirus pandemic.</li></ul>

Illumina Inc. has had a strong first quarter of 2024, which included an encouraging performance from its high throughput consumables, increased revenue from strategic partnerships, and the delivery of a number of NovaSeq X instruments.However, Chief Executive Officer Jacob Thaysen has warned about the persisting uncertain global economic environment and cited customer concerns affecting purchasing decisions.The year's results were particularly promising considering the challenges posed by the Coronavirus pandemic.

Illumina Inc.: Will Its Market Dominance In Genetic Analysis Last? - Major Drivers

<ul><li>Illumina reports a successful 2023 but is bracing for a challenging 2024 amid continued macroeconomic hurdles.</li><li>The company delivered a higher-than-expected consolidated revenue of approximately $1.12 billion in the fourth quarter, marking an increase of 4% year over year.</li><li>CEO Jacob Thaysen highlighted the latest product, NovaSeq X, as the most successful high-throughput product launch in the company's history.</li></ul>

Illumina reports a successful 2023 but is bracing for a challenging 2024 amid continued macroeconomic hurdles.The company delivered a higher-than-expected consolidated revenue of approximately $1.12 billion in the fourth quarter, marking an increase of 4% year over year.CEO Jacob Thaysen highlighted the latest product, NovaSeq X, as the most successful high-throughput product launch in the company's history.

Illumina Inc: Will Its Market Dominance In Genetic Analysis Last In The Long Term? - Major Drivers

<ul><li>Illumina delivered mixed results for the previous quarter, with revenues below the analyst consensus.</li><li>Despite lower revenue, non-GAAP net income surpassed expectations at $52 million or $0.33 per diluted share.</li><li>While Core Illumina sequencing consumables revenue dropped 4% year-over-year, clinical sequencing consumables experienced a 10% growth, mitigating the decline.</li></ul>

Illumina delivered mixed results for the previous quarter, with revenues below the analyst consensus.Despite lower revenue, non-GAAP net income surpassed expectations at $52 million or $0.33 per diluted share.While Core Illumina sequencing consumables revenue dropped 4% year-over-year, clinical sequencing consumables experienced a 10% growth, mitigating the decline.

Illumina Inc: The Inside Story of Steady Revenues and Strategic Expansions! - Major Drivers

<ul><li>Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.</li><li>Illumina exceeded its expectations, with approximately $1.18 billion in revenue and diluted non-GAAP EPS of $0.32.</li><li>In the quarter, the company sold 109 NovaSeq X instruments, and their team plans to offer more than 390 instruments over the entire year.</li></ul>

Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.Illumina exceeded its expectations, with approximately $1.18 billion in revenue and diluted non-GAAP EPS of $0.32.In the quarter, the company sold 109 NovaSeq X instruments, and their team plans to offer more than 390 instruments over the entire year.

Illumina Inc.: Unveiling the Growth Strategies That Spiked Clinical Sequencing! - Major Drivers

<ul><li>Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.</li><li>In Q1, Illumina produced revenue of about $1.09 billion.</li><li>Illumina also unveiled Illumina Complete Long-Read technology and Illumina Connected Insights.</li></ul>

Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.In Q1, Illumina produced revenue of about $1.09 billion.Illumina also unveiled Illumina Complete Long-Read technology and Illumina Connected Insights.

Illumina Inc.: Expansion of Genomics Capacity With New Pact & Other Drivers

United States

Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Illumina Inc (ILMN US)

Illumina Inc.: Will Its Market Dominance In Genetic Analysis Last? - Major Drivers

Illumina Inc. has had a strong first quarter of 2024, which included an encouraging performance from its high throughput consumables, increased...

Baptista Research

Illumina Inc: Will Its Market Dominance In Genetic Analysis Last In The Long Term? - Major Drivers

Illumina reports a successful 2023 but is bracing for a challenging 2024 amid continued macroeconomic hurdles. The company delivered a...

Baptista Research

Illumina Inc: The Inside Story of Steady Revenues and Strategic Expansions! - Major Drivers

Illumina delivered mixed results for the previous quarter, with revenues below the analyst consensus. Despite lower revenue, non-GAAP net income...

Baptista Research

Illumina Inc.: Unveiling the Growth Strategies That Spiked Clinical Sequencing! - Major Drivers

Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street. Illumina exceeded its expectations, with...

Baptista Research

Illumina Inc.: Expansion of Genomics Capacity With New Pact & Other Drivers

Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street. In Q1, Illumina produced revenue of...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)